Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 607.39 |
| Open | 612.06 |
| Bid | 611.80 x 800 |
| Ask | 617.00 x 800 |
| Day's range | 602.52 - 613.15 |
| 52-week range | 536.08 - 747.42 |
| Volume | |
| Avg. volume | 713,509 |
| Market cap | 67.28B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 8.71 |
| EPS (TTM) | 70.31 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 691.14 |
- Motley Fool
Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
- Zacks
Regeneron (REGN) Gains But Lags Market: What You Should Know
Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.
- PR Newswire
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The data were presented in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, taking place Jun
© 2022 Yahoo. All rights reserved.
